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Objective: Flavonoids, naturally-occurring compounds in fruits and vegetables, possess anti-coagulant property. However, a very few studies were 
attempted to understand how flavonoid structure influences its anti-coagulation property, such as clotting time. In this study, we investigated 
structurally similar flavonoid compounds which differ in the number of hydroxyl groups and compared their anti-coagulation properties.
Methods: We selected and evaluated five flavonoid compounds, that is, chrysin, apigenin, luteolin, kaempferol, and quercetin, for their anti-coagulant 
properties using in vitro prothrombin time (PT) assays and activated partial thromboplastin time (APTT) assay.
Results: Our findings suggested that quercetin, kaempferol, and luteolin showed a significant anti-coagulant effect on APTT (p<0.05) in a dose-
dependent manner. The dose of 500 µM quercetin showed potent prolong APTT with 37.43±1.60 s, followed by 500 µM of kaempferol and luteolin 
(34.63±1.29 s and 4.83±1.56 s, respectively). Furthermore, a combination of 500 µM of quercetin with 0.25 U/ml of heparin demonstrated prolong 
APTT (52.16±5.18 s) when compared with individual effects of either 0.25 U/ml heparin (33.4±0.50 s) or 500 µM quercetin (37.43±1.62 s) alone.
Conclusion: Our results demonstrated that numbers of the hydroxyl group on flavonoid compounds influence anti-coagulation properties. In 
addition, the prolonged APTT assay results suggested that quercetin, kaempferol, and luteolin could affect factors VIII, IX, XI, and XII of intrinsic 
pathway. Moreover, the synergistic effect of quercetin further enhances the heparin anti-coagulation effect. Based on our findings, we recommend 
that the consumption of vegetables and fruits rich in quercetin, luteolin, and kaempferol could help prevent thrombotic stroke in high-risk patients.
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INTRODUCTION
Non-communicable diseases, including diabetes mellitus (DM) and 
hypertension (HT), have been increased in both developing and 
developed countries [1]. DM and HT are well-established risk factors 
for stroke, wherein pathological conditions worsen blood vessel 
damage and stimulate excessive blood clotting [2-4]. In contrast, 
blood clotting is an important event during trauma and other 
vascular damages, where it plays pivotal role to stop bleeding and 
consequently seals up vascular damage, thus prevent blood loss. Two 
primary blood clotting pathways are (1) intrinsic pathway (factors 
VIII, IX, XI, and XII) and (2) extrinsic pathway (factor VII). Both 
pathways induce fibrin clot formation [5-7]. Patients with DM and 
HT are being treated with warfarin, heparin, and aspirin to prevent 
blood clotting and thus avoid life-threatening stroke condition [8]. 
In contrast, long-term use of these medical drugs on anti-coagulant 
treatment caused hemorrhagic risk [9]. This study was conducted to 
explore anti-coagulant ability of natural flavonoid compounds, and 
their potential being a safer alternative to prescribed anti-coagulant 
drugs.
Flavonoids, a natural-occurring compounds in fruits and vegetables, 
have been known for anti-platelet and anti-coagulant properties, both 
in vitro and in vivo [10]. However, the structure-functional relationship 
and possible mechanistic role of flavonoids as an anti-coagulant agent 
are not well studied. Our objective of this study was to investigate and 
compere the effect of flavonoids (chrysin, apigenin, luteolin, kaempferol, 
and quercetin) on the hemostasis through extrinsic and intrinsic 
pathways using in vitro prothrombin time (PT) assays and activated 
partial thromboplastin time (APTT) assay, respectively. In this study, 
we investigated anti-coagulant properties of flavonoids with different 
numbers of hydroxyl groups. We also investigated potential synergetic 
effect of flavonoids and a low dose of heparin, which can confirm if 
eating a diet rich in fruits and vegetables containing flavonoids could 
promote stroke prevention in hypertension and diabetic patients [11].
MATERIALS AND METHODS
Chemicals and reagents
Chrysin, apigenin, luteolin, kaempferol, and quercetin were purchased 
from Sigma-Aldrich (St. Louis, MO, USA). The chemical structures are 
shown in Fig. 1. Dimethyl sulfoxide (DMSO) was obtained from Merck 
(MA, USA).
Blood sampling and plasma preparation
Ten milliliters of venous blood samples were obtained from healthy 
volunteers without a history of bleeding or thrombosis (n=10, aged 
18–30 years) according to human blood collection which was approved 
by the Office of the Human Research Ethics Committees of Walailak 
University (protocol no. WUEC-18-024-01). Venous blood samples were 
transferred to blood collection tube (BD Vacutainer® sodium citrate 
tubes, Becton, Dickinson and Company, Franklin Lakes, NJ) containing 
0.105 M sodium citrate (9:1 v/v, blood: anti-coagulant) and then 
subjected to centrifugation (800 g, 10 min, and 25°C). The supernatant 
plasma was transferred to a new tube and stored at −80°C until use.
PT activity assay
PT assays were carried out following the coagulometer protocols as 
previously described [12] with modifications for each sample using 
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an automatic coagulation instrument (Humaclot Duo Plus, HUMAN, 
Wiesbaden, Germany). Briefly, 90 µl of plasma sample was incubated 
with 10 µl of test compounds (Chrysin, apigenin, luteolin, kaempferol, 
and quercetin) diluted in normal saline (final concentration of 250 and 
500 µM, 37°C). After 5 min pre-incubation, 100 µl of PT assay reagent 
(Thromborel® S, Siemens Healthcare Diagnostics Products GmbH, 
Germany) were added to initiate the reaction sassy and the clotting 
time was measured. One percent DMSO was used as vehicle control and 
heparin (2 IU/ml) (Cristalia®, Itapira, SP, Brazil) was used as a positive 
control.
APTT activity assay
In APTT activity assay, 90 µl of plasma sample collected from human 
volunteers were mixed with 10 µl of test compound (final concentration 
of 250 and 500 µM) at 37°C. After 5 min, pre-warmed aPTT reagent 
(Actin® FS APTT, Siemens Healthcare Diagnostics Products GmbH, 
Germany) was added to the mixture. Clotting time was measured after 
the addition of 50 µl of CaCl2 solution using automated coagulometer 
(Humaclot Duo Plus, HUMAN, Wiesbaden, Germany). One percent 
DMSO was used as vehicle control and 1 IU/ml heparin (Cristalia®, 
Itapira, SP, Brazil) was used as a positive control.
Statistical analysis
All data were expressed as means±SD of three measurements. Statistical 
comparisons of the prolonged time between test compounds and 
vehicle control (1% DMSO) were achieved by non-parametric indecent 
t-test using GraphPad Prism version 5.0 (San Diego, California). p-value 
<0.05 was considered statistically significant.
Anti-coagulation assays
Although flavonoids have been reported to prolong anti-coagulant 
effect on human blood sample – both in vitro and in vivo, the structure-
functional relationship of flavonoids (e.g., chrysin, apigenin, luteolin, 
kaempferol, and quercetin) has not been studied. We first determined 
Table 1: Effect of flavonoids on anti-coagulant activity based on 
PT and APTT of normal human plasma
Compounds Concentrations PT (s)a APTT (s)a
Vehicle control 0.5% DMSO 15.23±0.05 32.03±0.20
Heparin (Positive 
control)
1 IU/ml 14.60±0.57 37.50±0.96
2 IU/ml 15.70±0.37 53.00±3.48
3 IU/ml 17.53±0.24 >200
Chrysin 250 µM 15.07±0.41 31.87±0.67
500 µM 14.50±0.00 32.40±0.21
Apigenin 250 µM 14.83±0.65 32.03±0.20
500 µM 14.40±0.36 33.06±0.95
Luteolin 250 µM 13.83±0.05 29.83±1.01
500 µM 14.10±0.57 34.83±1.56*
Kaempferol 250 µM 14.25±0.05 31.20±0.28
500 µM 13.90±0.50 34.63±1.29*
Quercetin 250 µM 14.70±0.20 31.37±0.21
500 µM 6.30±0.85 37.43±1.60*
aMean±SD (n=10). *p<0.05, compared with the vehicle control group. 
PT: Prothrombin time, APTT: Activated partial thromboplastin time
Fig. 2: Combined effect of quercetin and heparin on APTT assay. 
*p<0.05, compared to individual effects (0.25 U/ml heparin and 
500 µM quercetin)
Fig. 1: The chemical structures of test compounds
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whether the prolongation of APTT and PT was due to the structure-
functional relationship of chrysin, apigenin, luteolin, kaempferol, and 
quercetin on healthy volunteer blood samples. All these flavonoids 
share the same backbone structure and differ in numbers of hydroxyl 
groups primarily. To differentiate the anti-coagulant mechanistic 
properties of flavonoids through extrinsic and/or intrinsic pathways, 
PT and APTT assays were performed, respectively. In PT and APTT 
assays, each flavonoid was incubated with a human blood sample 
for 5 min with different final concentrations of 250 and 500 µM and 
prolonged PT and APTT time were measured. As shown in the Table 1, 
an average PT and APTT on healthy volunteers were 15.23±0.05 s and 
32.03±0.20 s, respectively. Heparin was used as a positive control in this 
study. The results of PT and APTT assays demonstrated that flavonoids 
contained the higher anti-coagulant effect on APTT compared to 
PT assay, thus indicating that these flavonoids might interfere with 
intrinsic clotting cascade. Among test compounds, luteolin, kaempferol, 
and quercetin showed a significantly prolonged time of APTT assay in 
a dose-dependent manner. The dose of 500 µM quercetin showed the 
potent prolong APTT (37.43±1.60 s), followed by 500 µM of kaempferol 
(34.63±1.293 s) and luteolin (4.83±1.56 s).
The combined anti-coagulant effect of quercetin and heparin
Among flavonoids tests, quercetin exhibited the potent anti-coagulant 
activity against APTT assay. It is thus, we further determined the 
combined anti-coagulant effect of quercetin and heparin (a prescribed 
drug for anti-coagulant), whether a reduced dose of heparin in 
blood clotting formation. We then combine the low dose of heparin 
(0.25 U/ml) with the various concentration of quercetin (100, 250, and 
500 µM) in healthy blood plasma before the addition of anti-coagulant 
agent. The dose of 0.25 U/ml of heparin and 500 µM of quercetin could 
prolong aPTT with 52.16±5.18 s when compared to individual effects 
(0.25 U/ml heparin (33.4±0.50) and 500 µM quercetin (37.43±1.62)) 
(Fig. 2) suggesting that quercetin and heparin might have synergistic 
effects against blood clotting.
DISCUSSION
In the present study, we first determined the anticoagulant effect 
of flavonoids including chrysin, apigenin, luteolin, kaempferol, and 
quercetin, (all are naturally occurring flavonoid compounds found 
abundantly in the fruits in vegetables) on blood samples collected from 
healthy volunteers. Our results demonstrated anti-coagulant effect of 
luteolin, kaempferol, and quercetin on blood clotting through APTT assay, 
but not PT assay. These contrasting outcomes indicated that flavonoids 
could affect the intrinsic coagulation pathway and not extrinsic pathway.
On the beginning of the 21st century, the number of patients with non-
communicable diseases, including DM, HT, and stroke, has been increased 
from time to time [1-3]. These diseases could damage blood vessel and 
finally, blood clotting formation, leading to morbidity and mortality 
associated with stroke and cardiovascular [13]. Alternative medicines, 
such as herbal medicines, have been considered as a good source of anti-
coagulant agents [14]. At present, anti-coagulation research community 
is focused on identifying plant-based materials with anti-coagulant 
activities, to prevent early stroke recurrence during blood vessel damage 
in DM and HT patients [14]. Flavonoids, natural-occurring substances in 
fruits and vegetables, have been focused and previously been reported 
containing anti-coagulant effect both in vitro and in vivo.
Based on our results, where potent inhibitory effect of quercetin on 
clotting formation was observed, we further studied and determined 
that the combined effect of quercetin and heparin was more effective. 
As shown in Fig. 2, at low concentration of heparin 0.25 IU/ml 
contained low anti-coagulant activity; however, when we mixed 0.25 
IU/ml heparin together with 500 µM quercetin, the prolonged clotting 
time is significantly increased compared to either 500 µM quercetin or 
0.25 IU/ml heparin alone. The synergistic effect could be contributed 
due to differences in the mechanism of action of quercetin and heparin. 
Heparin reversibly binds to antithrombin III in the intrinsic pathway, 
resulting in the inactivation of blood clotting [15], whereas quercetin 
potentially interferes with complex VIII and XI activity. Complex VIII and 
XI play a role in the intrinsic blood clotting cascade [16]. Therefore, we 
believe that the different anti-coagulation activation targets of heparin 
and quercetin potentially increase the prolonged time of APTT assay.
As shown in Table 1, chrysin and apigenin, which contain 2 and 3 
hydroxyl groups, respectively, did not confer anti-coagulant activity. 
However, luteolin and kaempferol, containing 4 hydroxy groups, have 
shown increased prolonged clotting time, and quercetin containing 5 
hydroxy groups exhibited the most potent anti-coagulant effect in our 
findings. The data clearly suggested that the number of hydroxyl groups 
in the flavonoids could potentially contribute to anti-coagulation 
properties. Our current finding is supported by previous study, where 
Manolove et al. demonstrated that the position of the hydroxyl group 
in other non-flavonoid molecules confers anti-coagulant activity of the 
compounds [15]. The results of prolonged APTT implied that luteolin, 
kaempferol, and quercetin may affect factors VIII, IX, XI, and XII in the 
intrinsic pathway. This result is similar to the previous report of Kuntic 
et al., 2011 that rutin (quercetin-3-rutinoside) has been shown to 
inhibit factors VIII and IX of the intrinsic pathway [17].
CONCLUSION
We demonstrate that quercetin possesses the highest anticoagulant 
properties among tested flavonoids. We also demonstrated that the 
numbers of hydroxyl group in flavonoid compounds could affect their 
anti-coagulant properties. Based on our data and findings, we propose 
that consumption of vegetables and fruits containing flavonoids 
(including quercetin, luteolin, and kaempferol) could potentially 
prevent thrombotic stroke, especially in the DM or HT patients. 
Moreover, eating flavonoid-abundant fruits and vegetables might help 
lower the use of prescribed drugs for stroke prevention in DM and HT. 
The in vivo study of combining quercetin with chemotherapeutic drugs, 
for example, heparin needs to be further elucidated.
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